CN101028421A - Chinese medicine for treating chronic kidney failure - Google Patents
Chinese medicine for treating chronic kidney failure Download PDFInfo
- Publication number
- CN101028421A CN101028421A CNA2007100654903A CN200710065490A CN101028421A CN 101028421 A CN101028421 A CN 101028421A CN A2007100654903 A CNA2007100654903 A CN A2007100654903A CN 200710065490 A CN200710065490 A CN 200710065490A CN 101028421 A CN101028421 A CN 101028421A
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- chinese patent
- radix
- chronic kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 208000020832 chronic kidney disease Diseases 0.000 title abstract description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 title abstract description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 18
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 18
- 210000003734 kidney Anatomy 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 21
- 230000001684 chronic effect Effects 0.000 claims description 19
- 241001489978 Eupolyphaga Species 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 241000222640 Polyporus Species 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 10
- 235000005903 Dioscorea Nutrition 0.000 claims description 9
- 241000234273 Dioscorea Species 0.000 claims description 9
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 9
- 235000004879 dioscorea Nutrition 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 229940023488 pill Drugs 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 229940046011 buccal tablet Drugs 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- -1 suspensoid Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 3
- 241000131329 Carabidae Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 13
- 235000019634 flavors Nutrition 0.000 description 13
- 206010030113 Oedema Diseases 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000003932 urinary bladder Anatomy 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 206010013990 dysuria Diseases 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 206010030302 Oliguria Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Abstract
A Chinese medicine for treating chronic renal failure is prepared from more than 10 Chinese- medicinal materials including astragalus root, notoginseng, epimedium, ground beetle, etc.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine for the treatment of chronic kidney hypofunction, is that a kind of chronic kidney hypofunction for the treatment of is the Chinese patent medicine of raw material with the Chinese herbal medicine.Belong to the field of Chinese medicines.
Background technology
Chronic renal failure (chronic kidney hypofunction) is because the result of kidney damage that a variety of causes causes and the deterioration of carrying out property, body is at the excretion metabolism product, regulate water, electrolyte, acid-base balance, and the clinical syndrome that gets muddled of aspects such as the generation of some endocrine activity material and deactivation.Common clinically asthenia, feel sick, symptom such as vomiting, anemia, oliguria, edema and impaired renal function, Water-Electrolyte disorder etc.Chronic kidney hypofunction belongs to categories such as " difficulty in urination ", " obstruction and rejection ", " edema ", " asthenia " in the traditional Chinese medical science.
Chronic kidney hypofunction can be by multiple kidney disease development such as edema, stranguria, hematuria.The traditional Chinese medical science thinks that with the passing of time various nephropathy, undermine each function, and based on the spleen damage of suffering from a deficiency of the kidney, the state of an illness progressively develops and aggravates disease, and causes the positive deficiency of vital energy to decline at last, and turbid pathogen, blood stasis are stopped up the kidney network that stagnates, cause kidney to lose out entire function, the retention of turbid damp uremic is in body, and the initiation primary disease.In its evolution, often, some factor accelerates owing to making course of disease progress, and sb.'s illness took a turn for the worse.Common inducement such as being invaded by exogenous pathogen, eating and drinking without temperance, overstrain etc.The traditional Chinese medical science is divided into clinically: the dialectical treatments of disease type such as spleen deficiency of kidney-QI, deficiency of spleen-YANG and kidneyYANG, the hepatic and renal YIN deficiency, deficiency of both YIN and YANG, and the progress of delaying chronic kidney hypofunction, evident in efficacy.
The method of western medical treatment primary disease is a lot, comprises hemodialysis, peritoneal dialysis and renal transplantation etc., brings very heavy mental burden and financial burden for patient and household, and side effect is in various degree arranged.
Summary of the invention
The present invention develops in conjunction with the latest modern technological scientific achievement on the basis of traditional tcm syndrome differentiation and treatment.The purpose of this invention is to provide a kind of Chinese patent medicine for the treatment of chronic kidney hypofunction, and have determined curative effect, safe ready, little, the cheap characteristics of side effect.
The present invention is made by the following weight proportion raw material:
1.5～6 parts of 0.1～0.5 portion of Polyporus of 3～12 parts of Radix Notoginseng powder of Radix Astragali
1.0～4 parts of 0.1～2 portion of Rhizoma Alismatis of 1.5～6 parts of Eupolyphaga Seu Steleophagas of Herba Epimedii
1.0～4 parts of 0.1～2 portion of Rhizoma Dioscoreaes of 1.0～4 parts of Flos Sophorae of Radix Rehmanniae
0.1～2 part of 0.1～2 part of Ramulus Cinnamomi of 1.5～6 portions of Semen Plantaginiss of Rhizoma Smilacis Glabrae
The weight proportion of each raw material of optimization formula of the present invention is:
2.5～3.5 parts of 0.2～0.4 portion of Polyporus of 4～8 parts of Radix Notoginseng powder of Radix Astragali
1.5～2.5 parts of 0.5～1.5 portion of Rhizoma Alismatis of 2.5～3.5 parts of Eupolyphaga Seu Steleophagas of Herba Epimedii
1.5～2.5 parts of 0.5～1.5 portion of Rhizoma Dioscoreaes of 1.5～2.5 parts of Flos Sophorae of Radix Rehmanniae
0.5～1.5 part of 0.5～1.5 part of Ramulus Cinnamomi of 2.5～3.5 portions of Semen Plantaginiss of Rhizoma Smilacis Glabrae
The weight proportion of each raw material of optimum formula of the present invention is:
3 parts of 0.3 portion of Polyporus of 6 parts of Radix Notoginseng powder of Radix Astragali
2 parts of 1 portion of Rhizoma Alismatis of 3 parts of Eupolyphaga Seu Steleophagas of Herba Epimedii
2 parts of 1 portion of Rhizoma Dioscoreaes of 2 parts of Flos Sophorae of Radix Rehmanniae
1 part of 1 part of Ramulus Cinnamomi of 3 portions of Semen Plantaginiss of Rhizoma Smilacis Glabrae
Drug action mechanism among the present invention is as follows:
The Radix Astragali nature and flavor are sweet, warm.Return lung, spleen channel.Have benefit and defend consolidating superficial resistance, inducing diuresis to remove edema, poison holding, the effect of granulation promoting.That can treat that internal injury overstrain, diarrhea due to hypofunction of the spleen, proctoptosis, deficiency of vital energy blood prostration, metrorrhagia and leukorrhagia, spontaneous perspiration, night sweat, arthralgia due to stagnation of blood, edema, carbuncle do not burst or burst does not hold back and the disease of all weakness of QI blood deficiency etc.(Ji Yubin chief editor " Chinese medicine medicine for preventing pharmacology and application " Heilungkiang science tech publishing house 1999 version the 1074th page).
Sweet, the little hardship of Radix Notoginseng powder nature and flavor, temperature.Return liver, stomach, large intestine channel.Has the dissipating blood stasis hemostasis, the effect of subduing swelling and relieving pain.Can treat haematemesis, hemoptysis, epistaxis, have blood in stool, dysentery, metrorrhagia, lump in the abdomen, puerperal blood faints, retention of lochia, traumatic hemorrhage, breast ventral spine pain, fall and pounce on blood stasis, carbuncle pain, acute pharyngolaryngitis, Light-headedness, tinnitus, coronary heart disease, angina pectoris, acute necrosis sections enteritis, venom, bee sting, rheumatic arthritis disease, hypertension etc.(Ji Yubin chief editor " Chinese medicine medicine for preventing pharmacology and application " Heilungkiang science tech publishing house 1999 version the 60th page).
The Polyporus nature and flavor are sweet, light, flat.Return spleen, kidney, urinary bladder channel.Have diuresis eliminating dampness by diuresis, anticancer effect.Can treat dysuria, edema distension, beriberi, urinary system infection, diarrhoea, stranguria with turbid discharge, leukorrhagia etc.(Ji Yubin chief editor " Chinese medicine medicine for preventing pharmacology and application " Heilungkiang science tech publishing house 1999 version the 1122nd page).
Herba Epimedii nature and flavor suffering, sweet, warm.Return liver, kidney channel.Effect with kidney invigorating and YANG supporting, expelling wind and removing dampness, bone and muscle strengthening.Can treat that sexual impotence erectile problem, dribbling urination, muscles and bones contraction urgency, hemiplegia, weakness of the waist and knees, rheumatic arthralgia, extremity are meciless, climacteric hypertension disease, Mental fatigue are forgetful, neurasthenia, osteomyelitis etc.(Ji Yubin chief editor " Chinese medicine medicine for preventing pharmacology and application " Heilungkiang science tech publishing house 1999 version the 1143rd page).
The Eupolyphaga Seu Steleophaga nature and flavor are salty, cold, slightly poisonous.Return Liver Channel.Has promoting blood circulation to remove blood stasis, inducing menstruation to relieve menalgia, the abdominal mass that disappears, the effect of reunion of bone.Ke Zhi Liao lumps in the chest and abdomen, amenorrhea due to stagnation of blood, postnatal blood stasis stomachache, traumatic injury, swollen and rigid tongue, congenital deformity of the tongue, the muscles and bones folding is hindered hepatosplenomegaly, an emaciation due to blood disorder, scarlet fever, erysipelas etc.(Ji Yubin chief editor " Chinese medicine medicine for preventing pharmacology and application " Heilungkiang science tech publishing house 1999 version the 91st page).
The Rhizoma Alismatis nature and flavor are sweet, cold.Return kidney, urinary bladder channel.Has diuresis, the effect of clearing away damp-heat.Can treat dysuria, edema distension, the oliguria of having loose bowels, dizziness due to fluid-retention, the puckery pain of pyretic stranguria; Hyperlipidemia etc.(the 184th page of Chemical Industry Press of Pharmacopoeia of the People's Republic of China version in 2000 is compiled by Chinese Pharmacopoeia Commission).
The Radix Rehmanniae nature and flavor are sweet, cold.GUIXIN, liver, kidney channel.Has clearing away heat and cooling blood, yin nourishing, the effect of promoting the production of body fluid.Can treat that calentura crimson tongue excessive thirst, interior-heat caused by deficiency of YIN, hectic fever due to YIN-deficiency consumptive fever, interior-heat are quenched one's thirst, haematemesis, epistaxis, send out speckle dermexanthesis etc.(Ji Yubin chief editor " Chinese medicine medicine for preventing pharmacology and application " Heilungkiang science tech publishing house 1999 version the 514th page).
Flos Sophorae nature and flavor hardship is slightly cold.Return liver, large intestine channel.Has cooling blood for hemostasis, the effect of liver heat removing and eyesight improving.Cure mainly discharging fresh blood stool, the hemorrhoid hematochezia, dysentery with red and white feces, stranguria with blood, epistaxis, sore swollen toxin etc. are spitted blood in metrorrhagia.(the 3440th page of Shanghai science tech publishing house second edition write by " Chinese medicine voluminous dictionary " Nanjing University of Traditional Chinese Medicine).
The Rhizoma Dioscoreae nature and flavor are sweet, flat.Return spleen, lung, kidney channel.Have spleen reinforcing, support lung, reinforce the kidney, the effect that benefit is smart.Cure mainly diarrhea due to hypofunction of the spleen, the lack of appetite edema, cough and asthma due to lung deficiency is quenched one's thirst, seminal emission, leukorrhagia.The frequent micturition etc. of suffering from a deficiency of the kidney.(the 218th page of Shanghai science tech publishing house second edition write by " Chinese medicine voluminous dictionary " Nanjing University of Traditional Chinese Medicine).
The Rhizoma Smilacis Glabrae nature and flavor are sweet, light, flat.Return liver, stomach warp.Has heat-clearing and toxic substances removing, wind-damp dispelling, bone and muscle strengthening, sharp joint, anticancer effect.Can treat damp and hot sore, eczema, rheumatic ostalgia, limbs contracture, Fructus Myricae rubrae malignant boil, urinary system infection, syphilis, stranguria with turbid discharge, stranguria leucorrhea, dyspepsia, diarrhoea, beriberi, furuncle, carbuncle, scrofula etc.(Ji Yubin chief editor " Chinese medicine medicine for preventing pharmacology and application " Heilungkiang science tech publishing house 1999 version the 87th page).
The Semen Plantaginis nature and flavor are sweet, be slightly cold.Return liver, kidney, lung, small intestinal, urinary bladder channel.Has clearing away heat and promoting diuresis, eliminating dampness by diuresis antidiarrheal, liver heat removing and eyesight improving, the effect of removing heat from the lung and dissipating phlegm.Can treat the cough due to lung-heat, urinary system infection, calculus, gastritis, dysuria, enteritis, bacillary dysentery, acute icterohepatitisshock, bronchitis, acute eye conjunctivitis, stranguria with turbid discharge, leukorrhagia, hematuria, edema, hematodiarrhoea is had loose bowels, epistaxis, conjunctival congestion and swelling pain, sore throat tonsillitis, cough, skin ulcer etc.(Ji Yubin chief editor " Chinese medicine medicine for preventing pharmacology and application " Heilungkiang science tech publishing house 1999 version the 291st page).
Ramulus Cinnamomi nature and flavor suffering, sweet, warm.GUIXIN, bladder, lung meridian.Has the diaphoresis expelling pathogenic factors from muscles, warming the meridian and promoting blood circulation, the cold-damp of dispeling the wind, the horizontal logical podomere of row upper limb, activating YANG and prormoting functioning of QI, the effect of the flat gas that spins.Can treat exterior syndrome due to wind-cold, shoulder back of the body podomere is ached, thoracic obstruction phlegm retention, amenorrhea lump in the abdomen, rheumatic arthralgia, cold, cough with asthma phlegm retention, amenorrhea stomachache etc.(Ji Yubin chief editor " Chinese medicine medicine for preventing pharmacology and application " Heilungkiang science tech publishing house 1999 version the 980th page).
The present invention follows the principles of formulating prescriptions of the traditional Chinese medical science " monarch ", is monarch drug with Radix Astragali, Radix Notoginseng powder, Polyporus, Herba Epimedii and Eupolyphaga Seu Steleophaga, is ministerial drug with Rhizoma Alismatis, Radix Rehmanniae, Rhizoma Dioscoreae, Flos Sophorae and Rhizoma Smilacis Glabrae, is adjuvant with Semen Plantaginis and Ramulus Cinnamomi.All medicine phases and tool vital energy benefiting and the kidney invigorating altogether, the effect of inducing diuresis to remove edema, the treatment chronic kidney hypofunction has determined curative effect, has no side effect taking convenience, cheap characteristics.
Chinese patent medicine of the present invention, can add the medicine acceptable carrier when being prepared into medicament, described medicine acceptable carrier can be: starch, sucrose, lactose, mannitol, silicon derivative, cellulose family and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Chinese patent medicine of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, buccal tablet, granule, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, preferred Chinese patent medicine is a peroral dosage form, as: tablet, capsule, oral liquid, buccal tablet, granule, pill, powder, suspensoid, powder, solution, drop, drop pill.Preferred Chinese patent medicine is capsule, tablet, granule.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1, the Chinese herbal medicine each component selected for use of the present invention meets the regulation of The Drug Administration Law of People's Republic of China, utilizes the comprehensive function treatment chronic kidney hypofunction of the Chinese medicine of respectively distinguishing the flavor of, and is nontoxic to human body.Show that through animal acute toxicity experiment the animal of being tested does not see any toxic reaction, its main organs does not have tangible change yet, and safety of medicine is reliable.
2, the present invention need not decoct, no bitterness sense, rich in proteins in the medicine, glucose, glucuronic acid, volatile oil, pectin, fructose, organic acid, lecithin, vitamin, aminoacid, also contain various trace elements such as Saponin, plant sterol and calcium, be beneficial to absorption of human body, health invigorating, and taking convenience.
3, the present invention not only can effectively treat chronic kidney hypofunction, and the prevention of chronic kidney hypofunction is also had good effect, has improved patient's life quality greatly, and higher healing rehabilitation efficacy is arranged.
Chronic kidney hypofunction (difficulty in urination) diagnosis basis: (the 219th page of chief editor's " traditional Chinese medical science disease diagnosis and treatment standard and prescription are selected for use " People's Health Publisher's calendar year 2001 version such as Dai Shen).
1, dysuria, drop are not smooth, or urine is inaccessible obstructed, and urethra does not have puckery pain, little distention and fullness in the abdomen.
2, be more common in elderly men, or postpartum women and operation back patient.
3, prostate hyperplasia is checked in male's rectal touch, or the obvious voiced sound of bladder area percussion.
4, do inspections such as cystoscope, B ultrasonic, abdominal X-ray, help diagnosis.
Chronic kidney hypofunction (difficulty in urination) efficacy assessment standard: (the 222nd page of chief editor's " traditional Chinese medical science disease diagnosis and treatment standard and prescription are selected for use " People's Health Publisher's calendar year 2001 version such as Dai Shen).
1, cure: it is unobstructed to urinate, and symptom and sign disappear.
2, take a turn for the better: symptom and sign are improved.
3, do not heal: the symptom no change.
Further specify the therapeutic effect of medicine of the present invention below by the clinical practice example to the treatment chronic kidney hypofunction
As follows through clinical test results; Treatment chronic kidney hypofunction patient 97 examples.Take embodiment 1 capsule, each 2-10 grain, every day three to four times, eliminating cold for resuscitation water send down, and take half an hour ante cibum.Two months is a course of treatment, take continuously three the course of treatment observe the curative effect.Cure 51 examples and account for 52.58%, 35 examples that take a turn for the better account for 36.08%, and more 11 examples do not account for 11.34%, and total effective rate reaches 88.66%.After three course of therapy, patient's asthenia, feel sick, symptoms such as vomiting, anemia, oliguria, edema all have clear improvement.And patient does not have any untoward reaction, and three big routine tests and hepatic and renal function detect no abnormal.
The specific embodiment
Embodiment 1 capsule takes by weighing raw material by following weight:
3 parts of 0.3 portion of Polyporus of 6 parts of Radix Notoginseng powder of Radix Astragali
2 parts of 1 portion of Rhizoma Alismatis of 3 parts of Eupolyphaga Seu Steleophagas of Herba Epimedii
2 parts of 1 portion of Rhizoma Dioscoreaes of 2 parts of Flos Sophorae of Radix Rehmanniae
1 part of 1 part of Ramulus Cinnamomi of 3 portions of Semen Plantaginiss of Rhizoma Smilacis Glabrae
Preparation method is to get Radix Notoginseng powder drying and crushing to 120～200 order fine powders earlier, get Radix Astragali again, Polyporus, Herba Epimedii, Eupolyphaga Seu Steleophaga, Rhizoma Alismatis, Radix Rehmanniae, Flos Sophorae, Rhizoma Dioscoreae, Rhizoma Smilacis Glabrae, Semen Plantaginis and Ramulus Cinnamomi decoct with water twice, 1.5～2 hours for the first time, 0.5～1 hour for the second time, merge decocting liquid twice, filter, filtrate is concentrated into 80 degree～85 when spending, the clear paste of relative density 1.08～1.10, adding ethanol makes clear paste contain the alcohol amount to reach 70%, left standstill 24 hours, and reclaimed ethanol, when 50 degree～55 are spent, be concentrated into the clear paste of relative density 1.30～1.32, again with clear paste and Radix Notoginseng powder fine powder mixing, drying is ground into fine powder, incapsulates.Adorn 0.3 gram for every, usually half an hour ante cibum oral, eliminating cold for resuscitation water send down, one time 2～10, three to four times on the one, one month is a course of treatment.
Embodiment 2 tablets take by weighing raw material by following weight:
3 parts of 0.3 portion of Polyporus of 6 parts of Radix Notoginseng powder of Radix Astragali
2 parts of 1 portion of Rhizoma Alismatis of 3 parts of Eupolyphaga Seu Steleophagas of Herba Epimedii
2 parts of 1 portion of Rhizoma Dioscoreaes of 2 parts of Flos Sophorae of Radix Rehmanniae
1 part of 1 part of Ramulus Cinnamomi of 3 portions of Semen Plantaginiss of Rhizoma Smilacis Glabrae
Preparation method is to get Radix Notoginseng powder drying and crushing to 120～200 order fine powders earlier, get Radix Astragali again, Polyporus, Herba Epimedii, Eupolyphaga Seu Steleophaga, Rhizoma Alismatis, Radix Rehmanniae, Flos Sophorae, Rhizoma Dioscoreae, Rhizoma Smilacis Glabrae, Semen Plantaginis and Ramulus Cinnamomi decoct with water twice, 1.5～2 hours for the first time, 0.5～1 hour for the second time, merge decocting liquid twice, filter, filtrate is concentrated into 80 degree～85 when spending, the clear paste of relative density 1.08～1.10 adds ethanol and makes clear paste contain the alcohol amount to reach 70%, left standstill 24 hours, reclaim ethanol, when spending, 50 degree～55 are concentrated into the clear paste of relative density 1.30～1.32, again with clear paste and Radix Notoginseng powder fine powder mixing, drying, be ground into fine powder, add an amount of magnesium stearate, tabletting, sugar coating are promptly.Usually half an hour ante cibum oral, eliminating cold for resuscitation water send down, one time 2～10, three to four times on the one, one month is a course of treatment.
Embodiment 3 granules take by weighing raw material by following weight:
3 parts of 0.3 portion of Polyporus of 6 parts of Radix Notoginseng powder of Radix Astragali
2 parts of 1 portion of Rhizoma Alismatis of 3 parts of Eupolyphaga Seu Steleophagas of Herba Epimedii
2 parts of 1 portion of Rhizoma Dioscoreaes of 2 parts of Flos Sophorae of Radix Rehmanniae
1 part of 1 part of Ramulus Cinnamomi of 3 portions of Semen Plantaginiss of Rhizoma Smilacis Glabrae
Preparation method is to get Radix Notoginseng powder drying and crushing to 120～200 order fine powders earlier, get Radix Astragali again, Polyporus, Herba Epimedii, Eupolyphaga Seu Steleophaga, Rhizoma Alismatis, Radix Rehmanniae, Flos Sophorae, Rhizoma Dioscoreae, Rhizoma Smilacis Glabrae, Semen Plantaginis and Ramulus Cinnamomi decoct with water twice, 1.5～2 hours for the first time, 0.5～1 hour for the second time, merge decocting liquid twice, filter, filtrate is concentrated into 80 degree～85 when spending, the clear paste of relative density 1.08～1.10 adds ethanol and makes clear paste contain the alcohol amount to reach 70%, left standstill 24 hours, reclaim ethanol, when spending, 50 degree～55 are concentrated into the clear paste of relative density 1.30～1.32, again with clear paste and Radix Notoginseng powder fine powder mixing, drying, be ground into fine powder, add an amount of sucrose and soluble starch, alcohol granulation, the pack of dry back is promptly.Usually half an hour ante cibum warm boiled water, one time 1～3 bag, three to four times on the one, one month is a course of treatment.
Claims (6)
1, a kind of Chinese patent medicine for the treatment of chronic kidney hypofunction is characterized in that it is made by the following weight proportion raw material:
1.5～6 parts of 0.1～0.5 portion of Polyporus of 3～12 parts of Radix Notoginseng powder of Radix Astragali
1.0～4 parts of 0.1～2 portion of Rhizoma Alismatis of 1.5～6 parts of Eupolyphaga Seu Steleophagas of Herba Epimedii
1.0～4 parts of 0.1～2 portion of Rhizoma Dioscoreaes of 1.0～4 parts of Flos Sophorae of Radix Rehmanniae
0.1～2 part of 0.1～2 part of Ramulus Cinnamomi of 1.5～6 portions of Semen Plantaginiss of Rhizoma Smilacis Glabrae
2, a kind of Chinese patent medicine for the treatment of chronic kidney hypofunction according to claim 1, wherein the weight proportion of each raw material is:
2.5～3.5 parts of 0.2～0.4 portion of Polyporus of 4～8 parts of Radix Notoginseng powder of Radix Astragali
1.5～2.5 parts of 0.5～1.5 portion of Rhizoma Alismatis of 2.5～3.5 parts of Eupolyphaga Seu Steleophagas of Herba Epimedii
1.5～2.5 parts of 0.5～1.5 portion of Rhizoma Dioscoreaes of 1.5～2.5 parts of Flos Sophorae of Radix Rehmanniae
0.5～1.5 part of 0.5～1.5 part of Ramulus Cinnamomi of 2.5～3.5 portions of Semen Plantaginiss of Rhizoma Smilacis Glabrae
3, a kind of Chinese patent medicine for the treatment of chronic kidney hypofunction according to claim 1, wherein the weight proportion of each raw material is:
3 parts of 0.3 portion of Polyporus of 6 parts of Radix Notoginseng powder of Radix Astragali
2 parts of 1 portion of Rhizoma Alismatis of 3 parts of Eupolyphaga Seu Steleophagas of Herba Epimedii
2 parts of 1 portion of Rhizoma Dioscoreaes of 2 parts of Flos Sophorae of Radix Rehmanniae
1 part of 1 part of Ramulus Cinnamomi of 3 portions of Semen Plantaginiss of Rhizoma Smilacis Glabrae
4, the Chinese patent medicine of claim 1-3 is to be fit to medicinal various dosage forms.
5, the Chinese patent medicine of claim 4 is tablet, capsule, oral liquid, buccal tablet, granule, pill, powder, suspensoid, powder, solution, drop, drop pill.
6, the Chinese patent medicine of claim 4 is capsule, tablet, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710065490A CN101028421B (en) | 2007-04-16 | 2007-04-16 | Chinese medicine for treating chronic kidney failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710065490A CN101028421B (en) | 2007-04-16 | 2007-04-16 | Chinese medicine for treating chronic kidney failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101028421A true CN101028421A (en) | 2007-09-05 |
| CN101028421B CN101028421B (en) | 2010-05-19 |
Family
ID=38714078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710065490A Expired - Fee Related CN101028421B (en) | 2007-04-16 | 2007-04-16 | Chinese medicine for treating chronic kidney failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101028421B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785776A (en) * | 2010-04-02 | 2010-07-28 | 西北大学 | Application of ergot sterone in preparation of medicaments for treating chronic renal failure |
| CN101843695B (en) * | 2009-09-25 | 2011-07-27 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating chronic kidney failure |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1268355A (en) * | 2000-01-08 | 2000-10-04 | 陈柏林 | Yichanmanshenkang medicine for curing nephroses |
| CN1275630C (en) * | 2003-11-11 | 2006-09-20 | 国家中药现代化工程技术研究中心 | Medicine for treating chronic kidney failure and its preparing process |
-
2007
- 2007-04-16 CN CN200710065490A patent/CN101028421B/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843695B (en) * | 2009-09-25 | 2011-07-27 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating chronic kidney failure |
| CN101785776A (en) * | 2010-04-02 | 2010-07-28 | 西北大学 | Application of ergot sterone in preparation of medicaments for treating chronic renal failure |
| CN101785776B (en) * | 2010-04-02 | 2011-07-27 | 西北大学 | Application of ergot sterone in preparation of medicaments for treating chronic renal failure |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101028421B (en) | 2010-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101066445A (en) | Chinese medicine prepn for curing gastropathy radically | |
| CN102258658B (en) | Plaster for invigorating blood circulation and relieving pain | |
| CN1857584A (en) | Hypertension treating Chinese medicine preparation | |
| CN101028376A (en) | Chinese medicinal preparation for treating habitual abortion | |
| CN1943699A (en) | A Chinese traditional medicinal preparation for treatment of eczema | |
| CN101028506A (en) | Chinese-medicinal decoction for treating difficult menstruation | |
| CN100415278C (en) | A Chinese traditional medicinal preparation for treatment of eczema | |
| CN101085314A (en) | Chinese patent medicine for treating delayed menstruation | |
| CN100431578C (en) | Preparation of Chinese traditional medicine for treating hyperplasia of prostate | |
| CN101028421B (en) | Chinese medicine for treating chronic kidney failure | |
| CN100381141C (en) | Chinese medicine for treating prostatic hyperplasia | |
| CN100431592C (en) | Chinese medicinal formulation for treating hyperplasia of prostate | |
| CN101028492B (en) | Chinese preparation for treating hysteromyoma | |
| CN100415288C (en) | A Chinese traditional medicinal preparation for treatment of psoriasis | |
| CN1857450A (en) | Chinese medicine prepn for treating dysmenorrhea | |
| CN1253196C (en) | Medicine for treating colitis | |
| CN100450537C (en) | Chinese medicinal formulation for treating prostate hyperplasia | |
| CN100571725C (en) | A kind of Chinese medicine preparation for the treatment of sciatica | |
| CN102961662B (en) | Medicine for treating gastric ulcer and preparation method thereof | |
| CN101020032A (en) | Chinese medicine prepn for treating ischemic femoral head necrosis | |
| CN101066428A (en) | Medicine for treating sterility of aspermia and its prepn process | |
| CN101028404A (en) | Chinese-medicinal decoction for treating difficult menstruation | |
| CN101049444A (en) | Preparation of Chinese traditional medicine for treating urethritis in non-gonococcus | |
| CN101085338A (en) | Traditional Chinese medicine preparation for curing uric acid nephritis | |
| CN101028445A (en) | Chinese medicine for treating ichthyosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SINO-AMERICA INNOVATION UNITED INTERNATION Free format text: FORMER OWNER: BEIJING YIXINTANG MEDICINE INST. Effective date: 20110719 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 102300 NO. 2, YARD 191, DONGYANGTUO VILLAGE, JUNZHUANG TOWN, MENTOUGOU DISTRICT, BEIJING TO: 100076 NO. 10, EAST ALLEY 6, NORTH AREA, MINSHENG ROAD, VILLAGE 4, XIHONGMEN TOWN, DAXING DISTRICT, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110719 Address after: 100076, No. six, No. 10, North East Road, Minsheng Road, fourth village, Xihongmen Town, Beijing, Daxing District Patentee after: Beijing Sino US Joint Institute of innovation and international difficult diseases Address before: Yang Tuo Cun 102300 Beijing city Mentougou District Jun Zhuang Zhen Dong Hospital No. 191 No. 2 Patentee before: Beijing Yixintang Medicine Inst. |
|
| ASS | Succession or assignment of patent right |
Owner name: CHEN YUTANG Free format text: FORMER OWNER: BEIJING SINO-US INNOVATION INSTITUTE OF INTERNATIONAL STUBBORN DISEASES Effective date: 20120316 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Yutang Inventor before: Wang Xinsuo |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG XINSUO TO: CHEN YUTANG |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120316 Address after: 100076, Beijing Town, Daxing District Town, Xihongmen, four village, Minsheng Road, North East six, No. 10 Patentee after: Chen Yutang Address before: 100076, No. six, No. 10, North East Road, Minsheng Road, fourth village, Xihongmen Town, Beijing, Daxing District Patentee before: Beijing Sino US Joint Institute of innovation and international difficult diseases |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SINO-US INNOVATION UNITED INTERNATIONAL IN Free format text: FORMER OWNER: CHEN YUTANG Effective date: 20120419 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120419 Address after: 100076, Beijing Daxing District Xihongmen town fourth village Minsheng Road North East six 10, Beijing Sino US Joint Innovation Institute of international difficult disease Chen Zhonghua Dean Patentee after: Beijing Sino US Joint Institute of innovation and international difficult diseases Address before: 100076, Beijing Town, Daxing District Town, Xihongmen, four village, Minsheng Road, North East six, No. 10 Patentee before: Chen Yutang |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SINA-AMERICA INNOVATION UNITED INTERNATION Effective date: 20121017 Owner name: BEIJING CHINESE AND FOREIGN XINCHUANG INTERNATIONA Free format text: FORMER OWNER: BEIJING SINA-AMERICA INNOVATION UNITED INTERNATIONAL DIFFICULT DISEASE RESEARCH INSTITUTE Effective date: 20121017 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100076 DAXING, BEIJING TO: 100012 CHAOYANG, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121017 Address after: 100012 Beijing city Chaoyang District Shangli Road No. 201 Beijing Chinese New International Medical Research Institute Patentee after: Beijing new China International Pharmaceutical Research Institute Patentee after: Beijing Sino US Joint Institute of innovation and international difficult diseases Address before: 100076, Beijing Daxing District Xihongmen town fourth village Minsheng Road North East six 10, Beijing Sino US Joint Innovation Institute of international difficult disease Chen Zhonghua Dean Patentee before: Beijing Sino US Joint Institute of innovation and international difficult diseases |
|
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: BEIJING SINA-AMERICA INNOVATION UNITED INTERNATIONAL DIFFICULT DISEASE RESEARCH INSTITUTE Effective date: 20121121 Owner name: BEIJING JINKUI CHINESE MEDICAL RESEARCH INSTITUTE Free format text: FORMER OWNER: BEIJING CHINESE AND FOREIGN XINCHUANG INTERNATIONAL MEDICAL RESEARCH INSTITUTE Effective date: 20121121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Lin Wanshuo Inventor before: Chen Yutang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHEN YUTANG TO: LIN WANSHUO Free format text: CORRECT: ADDRESS; FROM: 100012 CHAOYANG, BEIJING TO: 100010 DONGCHENG, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121121 Address after: 100010, No. 3-1, building 3, Beijing Hutong, Dongcheng District, China Patentee after: Beijing Jingui Chinese Medicine Research Institute Co. Ltd. Address before: 100012 Beijing city Chaoyang District Shangli Road No. 201 Beijing Chinese New International Medical Research Institute Patentee before: Beijing new China International Pharmaceutical Research Institute Patentee before: Beijing Sino US Joint Institute of innovation and international difficult diseases |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20200416 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |